Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

Clinical Therapeutics

Volumn 27, Issue 8, 2005, Pages 1181-1195

  Buse, John B ^a   Rubin, Cindy J ^b   Frederich, Robert ^b   Viraswami Appanna, Kalyanee ^b   Lin, Kwo Chuan ^c   Montoro, Rafael ^d   Shockey, Gerald ^e   Davidson, Jaime A ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d Clinic of Physicians and Surgeons ^*

^e Endocrine and Diabetes Associates of Texas   (United States)

Author keywords

Dual ( ) PPAR activator; Oral antidiabetic therapy; PPAR agonist; Treatment option; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FATTY ACID; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DIETARY INTAKE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUNGER; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MONOTHERAPY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLYCINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OXAZOLES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 25844436624     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.08.005     Document Type: Article

References (28)

1. American Diabetes Association Standards of medical care in diabetes (position statement) Diabetes Care 27 Suppl 1 2004 S15 S35
2. DeFronzo RA, Bonadonna RC, and Ferrannini E Pathogenesis of NIDDM. A balanced overview Diabetes Care 15 1992 318 368
3. DeFronzo RA, and Ferrannini E Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease Diabetes Care 14 1991 173 194
4. Boden G, and Laakso M Lipids and glucose in type 2 diabetes: What is the cause and effect? Diabetes Care 27 2004 2253 2259
5. Schoonjans K, Staels B, and Auwerx J Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression J Lipid Res 37 1996 907 925
6. Presented at Mosqueda-Garcia R, Frost CE, and Swaminathan A Glucose lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPAR α/γ dual agonist, in type 2 diabetic patients Orlando, Fla. Abstract 138-OR 64th Scientific Sessions of the American Diabetes Association June 4-8 2004
7. Presented at Frost CE, Swaminathan A, and Raymond R Lipid lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPAR α/γ dual agonist, in type 2 diabetic patients Orlando, Fla. Abstract 1988-PO 64th Scientific Sessions of the American Diabetes Association June 4-8 2004
8. Boost® Web site. Available at: www.boost.com/boostdrinkhcp.html. Accessed May 19, 2005.
9. Otvos JD, Jeyarajah EJ, and Cromwell WC Measurement issues related to lipoprotein heterogeneity Am J Cardiol 90 2002 22i 29i
10. Wallace TM, Levy JC, and Matthews DR Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495
11. for the Rosiglitazone Clinical Trials Study Group Phillips LS, Grunberger G, and Miller E Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [published correction appears in Diabetes Care. 2001;24:973] Diabetes Care 24 2001 308 315
12. for the Pioglitazone 001 Study Group Aronoff S, Rosenblatt S, and Braithwaite S Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study Diabetes Care 23 2000 1605 1611
13. Rohlfing CL, Wiedmeyer HM, and Little RR Defining the relationship between plasma glucose and HbA(1c): Analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial Diabetes Care 25 2002 275 278
14. Picard F, and Auwerx J PPAR(gamma) and glucose homeostasis Annu Rev Nutr 22 2002 167 197
15. Stumvoll M, and Haring H Insulin resistance and insulin sensitizers Horm Res 55 Suppl 2 2001 3 13
16. Stefan N, Fritsche A, Haring H, and Stumvoll M Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferators-activated receptor-gamma2 gene Diabetes 50 2001 1143 1148
17. Jeng CY, Sheu WH, and Fuh MM Gemfibrozil treatment of endogenous hypertriglyceridemia: Effect on insulin-mediated glucose disposal and plasma insulin concentrations J Clin Endocrinol Metab 81 1996 2550 2553
18. Haffner SM the American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 Suppl 1 2004 S68 S71
19. National Cholesterol Education Program/Adult Treatment Panel III. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed May 19, 2005.
20. Grundy SM Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy Circulation 106 2002 2526 2529
21. Packard CJ, and Saito Y Non-HDL cholesterol as a marker of atherosclerotic risk J Atheroscler Thromb 11 2004 6 14
22. Watson KE, Horowitz BN, and Matson G Lipid abnormalities in insulin resistant states Rev Cardiovasc Med 4 2003 228 236
23. Rosenson RS, Otvos JD, and Freedman DS Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial Am J Cardiol 90 2002 89 94
24. Superko HR Small, dense, low-density lipoprotein and atherosclerosis Curr Atheroscler Rep 2 2000 226 231
25. Lamarche B, Lemieux I, and Despres JP The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, pathophysiology and therapeutic aspects Diabetes Metab 25 1999 199 211
26. [published correction appears in Med J Aust. 2002;177:396] O'Moore-Sullivan TM, and Prins JB Thiazolidinediones and type 2 diabetes: New drugs for an old disease Med J Aust 176 2002 381 386
27. Nesto RW, Bell D, and Bonow RO Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association, October 7, 2003 Circulation 108 2003 2941 2948
28. de Souza CJ, Eckhardt M, and Gagen K Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance Diabetes 50 2001 1863 1871